Healthcare Industry News: Elan Corp
News Release - December 6, 2011
Amneal Announces Corporate Business Development TeamAppointments underscore company focus on global expansion
BRIDGEWATER, N.J.--(Healthcare Sales & Marketing Network)-- Amneal Pharmaceuticals, LLC, a fast-growing manufacturer of generic drugs, today announced key additions to its corporate business development team:
Joseph Todisco has joined Amneal as Senior Vice President of Global Corporate Strategy & Business Development. He is responsible for the growth of the company’s domestic generic business as well as the development of Amneal’s global presence through partnerships, mergers and acquisitions, and the strategic deployment of existing commercial assets. Mr. Todisco was most recently Vice President of Business Development at Ranbaxy, Inc. where he was responsible for the firm’s U.S. business strategy. Prior to Ranbaxy, he held various positions in marketing, R&D and business development with Par Pharmaceutical Companies, Inc. Mr. Todisco received an MBA from Fordham University’s Graduate School of Business and a BA in economics from Georgetown University.
Dr. Narasimhan Mani is Director, Global Business Development and Portfolio. He heads the identification and execution of strategic international opportunities and alliances as well as R&D product management, product selection and corporate portfolio management. Prior to Amneal, Dr. Mani was Business Development Manager at Johnson & Johnson, where he was involved in business development, finance and strategic planning. He also acquired product development expertise in both branded and generic drugs at Elan Corporation, Forest Laboratories and Par Pharmaceuticals. Dr. Mani holds a PhD in pharmaceutics from the University of Georgia and an MBA from Columbia University.
Pranav Mehta is Global Director of Purchasing at Amneal. He oversees R&D procurement, commercial APIs, excipients and packaging for all corporate locations. He also ensures effective communications between internal teams and external vendors to meet R&D project timelines and manages strategic supply chain relationships worldwide. Since 2005, Mr. Mehta has been one of the key drivers in Amneal’s growth. Before joining Amneal, he began his career with JPMorgan Chase & Co. and received an MBA from the University of Houston.
Hanumantha Rao is Director of Business Development. He champions Amneal’s international expansion strategy by forging strategic alliances across Europe, Asia, India, Africa and the Middle East. Prior to Amneal, Mr. Rao was Associate Director – Strategic Sourcing & Business Development for North America and Europe at Dr. Reddy’s Laboratories Ltd. In earlier roles at Dr. Reddy’s and Ranbaxy, he gained experience in emerging markets and held leadership positions in sales and marketing, OTC and ethical brand management and business development. Mr. Rao holds a Masters in international management from Pondicherry Central University in India.
“In all areas of Amneal, we have placed tremendous importance on ensuring we have the absolute best people in each role,” said Chirag Patel, Amneal’s President. “This business development team reconfirms that commitment. We have assembled a powerful group of highly experienced, extremely knowledgeable professionals who share our vision for Amneal and will make a significant contribution to our exemplary growth,” added Patel.
Amneal Pharmaceuticals, LLC, with principal offices in Bridgewater, NJ, is a U.S.-based firm that develops, manufactures and distributes generic pharmaceuticals regulated and approved by the U.S. FDA. Known as “Generic’s New Generation,” the company utilizes its newly expanded R&D and manufacturing capabilities to conceive breakthrough developments with lasting impact for a robust product pipeline. Efficient ANDA approvals and diverse product acquisitions are key to Amneal’s aggressive growth strategy, as is the company’s strong commitment to deep customer relationships and maximum value creation. Amneal delivers high-quality products, superior service levels and dynamic value throughout the pharmaceutical industry. For more information, visit www.amneal.com.
Source: Amneal Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.